Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
l-tyrosine-adsorbed hymenoptera venom immunotherapy
- Development stage
- Unknown
- Lead developer
- ANALLERGO
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
L-tyrosine-adsorbed hymenoptera venom immunotherapy is a subcutaneous allergen immunotherapy (SCIT) product developed by ANALLERGO S.p.A. for the treatment of Hymenoptera venom allergies. The product contains standardized venom extracts from honeybees (Apis mellifera), common wasps (Vespula spp.), European hornets (Vespa crabro), and paper wasps (Polistes spp.). These allergens are adsorbed onto L-tyrosine, which acts as a depot adjuvant to provide a slow-release mechanism. This formulation is designed to improve local tolerability at the injection site while maintaining the clinical immunogenicity required to induce immune tolerance. The therapy is administered via subcutaneous injection under medical supervision, typically following clustered or rush build-up protocols, and has demonstrated high efficacy in preventing systemic allergic reactions upon re-sting.
- Other names
- L-tyrosine-adsorbed venom immunotherapytyrosine-adsorbed hymenoptera venom extractSubcutaneous Immunotherapy - L-Tyrosine-Adsorbed for Hymenoptera Venom
02
Targets
European hornet venom allergen (Vesp c)Polistes venom allergensVespula venom allergenHoney bee venom allergens
Beyond the preview
Go deeper on l-tyrosine-adsorbed hymenoptera venom immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on l-tyrosine-adsorbed hymenoptera venom immunotherapy.